Skip to main content
Equibles
JAZZ logo

JAZZ · Jazz Pharmaceuticals plc · Metrics

Track JAZZ — free

Use JAZZ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JAZZ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$227.76 -4.59 (-1.98%) At close · Sep 30
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$15.45B
Shares
64.91M
Volume · Sep 30 1.01M Avg daily vol (3M) 862.33K

JAZZ metrics

85 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$232.35
Market cap
$15.45B

Price action

20 metrics
Price change (1W)
-3.4%
Price change (30D)
-7.3%
Price change (3M)
-3.6%
Price change (6M)
+22.9%
Price change (YTD)
+36.7%
Price change (1Y)
+80.1%
Trailing year
Price change (5Y)
+76.5%
52-week high
$261.62
52-week low
$129.02
Change from 52-week high
-11.2%
Change from 52-week low
+80.1%
Annualized volatility
37.2%
Annualized volatility (3M)
27.3%
Beta
0.6
RSI (14D)
36.7
Price vs SMA 50
-6.5%
Price vs SMA 200
+10.2%
Avg volume (3M)
862,334
Relative volume
0.9
Average dollar volume
$213.73M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
64.91M

Valuation

12 metrics
P / E (TTM)
15.9
Trailing earnings · reciprocal yield 6.3%
PEG ratio
—
EV / revenue
4.0×
reciprocal yield 25.3%
EV / EBITDA
—
EV / EBIT
20.3×
reciprocal yield 4.9%
P / sales
3.4×
reciprocal yield 29.8%
P / book
3.2
reciprocal yield 31.1%
FCF yield
10.3%
TTM · current market cap
Buyback yield
0.0%
P / FCF
9.7
reciprocal yield 10.3%
P / operating cash flow
9.3
reciprocal yield 10.8%
Earnings yield
6.1%

Historical valuation

8 metrics
P / E historical average (3Y)
495.8×
reciprocal yield 0.2%
P / E historical average (5Y)
432.8×
reciprocal yield 0.2%
EV / revenue historical average (3Y)
3.1×
reciprocal yield 31.8%
EV / revenue historical average (5Y)
3.6×
reciprocal yield 27.5%
EV / EBIT historical average (3Y)
53.8×
reciprocal yield 1.9%
EV / EBIT historical average (5Y)
61.5×
reciprocal yield 1.6%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
—
Operating margin
19.5%
Trailing 12 months
Net margin
20.4%
Gross profit (TTM)
$2.20B
Operating profit (TTM)
$896.86M
Net income (TTM)
$940.75M
Trailing 12 months
Diluted EPS (TTM)
$14.63
FCF margin
34.6%
Effective tax rate
-29.3%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$70.30

Growth

11 metrics
Revenue growth YoY
+15.5%
Year over year
Net income growth YoY
-163.6%
Revenue (TTM)
$4.60B
Trailing 12 months
EPS growth YoY
-167.5%
Shares change YoY
+13.4%
Year over year · more shares
Revenue CAGR (3Y)
+5.3%
Revenue CAGR (5Y)
+12.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+1.4%
FCF CAGR (5Y)
+8.0%

Quality

14 metrics
Return on equity
19.6%
Return on assets
8.5%
Debt / equity
0.9
Current ratio
1.8
EBITDA (TTM)
—
Free cash flow (TTM)
$1.59B
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$2.73B
Latest balance sheet
Cash & equivalents
$1.62B
Total assets
$11.08B
Total debt
$4.35B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.66B
Capital expenditures (TTM)
$69.75M
R&D (TTM)
$815.64M
SG&A (TTM)
$1.68B
Stock compensation (TTM)
$306.73M
R&D / revenue
17.7%
Stock compensation / revenue
6.7%

Ownership (13F)

3 metrics
13F filers
653
13F filer change QoQ
+73
Institutional ownership
99.8%

Short interest

3 metrics
Short interest
7.2%
Latest settlement · 7.2 days to cover
Days to cover
7.2d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$23.00M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1232524 CUSIP G50871105 13F (30d) 15 filings 13 filers Visit website Investor relations